ORIC Pharmaceuticals, Inc. Appoints Christian V. Kuhlen as General Counsel
April 02, 2020 at 07:29 pm IST
Share
ORIC Pharmaceuticals, Inc. announced that Christian V. Kuhlen, M.D., has been named General Counsel. Dr. Kuhlen will serve on the executive leadership team and lead ORIC's legal, compliance, intellectual property, and corporate governance functions. Dr. Kuhlen has extensive depth and breadth of expertise as General Counsel for biotechnology companies, where he has been responsible for legal, SEC, human resources, intellectual property, and corporate governance functions. Most recently, Dr. Kuhlen served as General Counsel and Secretary for Synthorx, where he led the legal aspects of its initial public offering and advised on the company's subsequent acquisition by Sanofi.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.